radiation response modifier senolytic See: Lelarge, V., Capelle, R., Oger, F. et al. Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients’ treatment. npj Aging 10, 12 (2024). https://doi.org/10.1038/s41514-024-00138-4 http://orcid.org/0000-0002-5111-7263,https://orcid.org/0000-0001-9227-0670 A senolytic is a type of drug or compound that selectively induces the death, removal or both of senescent cells—cells that have stopped dividing but often remain metabolically active, often secreting inflammatory and harmful molecules. These cells accumulate with age and contribute to aging-related diseases, chronic inflammation, and tissue dysfunction. Senolytics work by targeting specific survival pathways that senescent cells rely on, such as the BCL-2 family proteins, PI3K/AKT pathway, or p53-related mechanisms. By eliminating these cells, senolytics have shown potential in improving tissue function, delaying age-related diseases, and enhancing healthspan in preclinical studies.